ArticleNature communications2021
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
8.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 143 citations in OpenAlex.
- Cellular senescence: six decades of discovery and reinvention.The EMBO journal · 2026Review
- MAPK-driven MYC/p21 axis controls senescence bypass and BCL-XL dependence in vincristine-resistant rhabdomyosarcoma.iScience · 2026Article
- Proteolysis Targeting Chimera (PROTAC) Linkerology Enhances the CDK-Degradation Selectivity Profile of a Multi-CDK Inhibitor: Discovery of Potent, Anti-Leukemic CDK9 Degraders.ACS pharmacology & translational science · 2026Article
- Recent advances of dual PROTACs for potential therapeutic applications.Molecular diversity · 2026Review
- Alcohol reshapes liver zonal plasticity and immune-metabolic reprogramming in metabolic-syndrome associated hepatocellular carcinoma.Nature communications · 2026Article
- Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Targeting cellular senescence alleviates bone marrow aging.bioRxiv : the preprint server for biology · 2026Article
- TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways.Cell death and differentiation · 2026Article
- Identification of a mechanism-based binding mode for a histone deacetylase 6 inhibitor.Nature communications · 2026Article
- Insights into the therapeutic strategies for aging and aging-associated diseases.Signal transduction and targeted therapy · 2026Review
- Targeting "undruggable" cancer proteins: pharmacological challenges and emerging strategies.Translational cancer research · 2026Review
- Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry.Chemical science · 2026Article
- Development of PolyHis-Targeting PROTAC Degraders.Angewandte Chemie (International ed. in English) · 2026Article
- Indirect ubiquitination independent of endogenous ubiquitination machinery for targeted protein degradation.Communications chemistry · 2026Article
- Computational Modeling of PROTAC Ternary Complexes as Ensembles Using SILCS-xTAC.Journal of chemical information and modeling · 2026Article
- PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models.Journal of experimental & clinical cancer research : CR · 2026Article
- Cholinesterase Inhibition and Anticancer Properties of [4-(Benzyloxy) phenyl]{Methylidene}hydrazinylidene]-1,3-dihydro-2H-Indol-2-ones Using Swiss Target-guided Prediction.Current computer-aided drug design · 2026Article
- TDTAC: a generalized time-dependent torsion angle correlation framework for resolving directional coordination in large biomolecular assemblies.Frontiers in molecular biosciences · 2026Article
- Navitoclax acts synergistically with irradiation to induce apoptosis in preclinical models of H3K27M-altered diffuse midline glioma.Scientific reports · 2025Article
- Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 3 institutions in 1 country.
Dongwen Lv *Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0003-4677-8996
Pratik Pal *Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Xingui LiuDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Yannan JiaDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Dinesh ThummuriDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Peiyi ZhangDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Wanyi HuDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Jing PeiDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Qi ZhangDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7918-8952
Shuo ZhouDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Sajid KhanDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0003-1331-8846
Xuan ZhangDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0001-6062-6708
Nan HuaDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Qingping YangDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Sebastian ArangoDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Weizhou ZhangDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-8236-0346
Digant NayakDepartment of Biochemistry & Structure Biology, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0003-3680-0846
Shaun K OlsenDepartment of Biochemistry & Structure Biology, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-1265-7101
Susan T WeintraubDepartment of Biochemistry & Structure Biology, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Robert HromasMays Cancer Center, the Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Marina KonoplevaDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9347-2212
Yaxia YuanDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA. yaxia.yuan@cop.ufl.edu.
Guangrong ZhengDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA. zhengg@cop.ufl.edu.ORCID http://orcid.org/0000-0002-8106-6663
Daohong ZhouDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA. zhoudaohong@cop.ufl.edu.ORCID http://orcid.org/0000-0002-2400-6461
University of Florida · USThe University of Texas Health Science Center at San Antonio · USThe University of Texas MD Anderson Cancer Center · US
Funding
EEPD1 Repair of Stressed Replication ForksR01CA205224 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robert A Hromas · 2016 to 2026
$3.3MStructural Biology of the Ubiquitin Conjugation SystemR01GM115568 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI OLSEN, SHAUN · 2015 to 2023
$2.7MInhibition of Bcl-xL by Targeted DegradationR01CA241191 · NCI · UNIVERSITY OF FLORIDA · PI KONOPLEVA, MARINA Y, ZHENG, GUANGRONG · 2020 to 2024
$2.6MUse of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancerR01CA242003 · NCI · UNIVERSITY OF FLORIDA · PI TREVINO, JOSE G., ZHENG, GUANGRONG · 2019 to 2023
$2.6MDevelop BCL-xL proteolysis targeting chimeras as safer and better senolyticsR01AG063801 · NIA · UNIVERSITY OF FLORIDA · PI ELISSEEFF, JENNIFER H, ZHENG, GUANGRONG · 2019 to 2023
$2.6MStructure and Function of the Essential Cell Cycle Regulator Cdc34R01GM128731 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Shaun Olsen · 2019 to 2026
$2.5MProteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasisR01CA260239 · NCI · UNIVERSITY OF FLORIDA · PI ZHANG, WEIZHOU · 2021 to 2025
$2.5MObesity, inflammation and breast cancerR01CA200673 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7MCD177 suppresses breast-cancer development by inhibiting beta-cateninR01CA203834 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7MCancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RR200030NCI NIH HHS R01 CA200673NCI NIH HHS R01 CA203834NCI NIH HHS R01 CA205224NCI NIH HHS R01 CA241191NCI NIH HHS R01 CA242003NCI NIH HHS R01 CA260239NIA NIH HHS R01 AG063801NIGMS NIH HHS R01 GM115568NIGMS NIH HHS R01 GM128731
Abstract
PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug development platform. However, most PROTACs have been generated empirically because many determinants of PROTAC specificity and activity remain elusive. Through computational modelling of the entire NEDD8-VHL Cullin RING E3 ubiquitin ligase (CRL
Indexed as
Antineoplastic Agentsbcl-X ProteinCell LineCell SurvivalHumansLeukemiaLysineModels, MolecularProteasome Endopeptidase ComplexProtein BindingProtein ConformationProteolysisProto-Oncogene Proteins c-bcl-2Small Molecule LibrariesUbiquitinationUbiquitin-Conjugating EnzymesAntineoplastic AgentsBCL2L1 protein, humanBCL2 protein, humanbcl-X ProteinLysineProteasome Endopeptidase ComplexProto-Oncogene Proteins c-bcl-2Small Molecule LibrariesUbiquitin-Conjugating EnzymesUbiquitin-Protein LigasesVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.